What Torigen Pharmaceuticals does

Torigen Pharmaceuticals is a Farmington, Connecticut-based veterinary oncology company founded in 2013 that operates a vertically integrated platform spanning cancer diagnostics and personalized immunotherapy for companion animals. The company's core technology combines Torigen Specialty Pathology (TSP), a diagnostic service that delivers expert pathological evaluations with 3-6 day turnaround, with VimClara, described as the first-ever autologous cancer vaccine kit designed to produce personalized cancer vaccines from a patient's own tumor tissue. Supporting products include the free TSP Kit for formalin-fixed tissue histopathology and the free Tumor Collection Kit (TCK) for fresh tissue submission that preserves the option for downstream VimClara immunotherapy production.

The company employs a freemium-led, channel-driven go-to-market model. Tumor Collection Kits and TSP Kits are provided at no charge to veterinary clinics, lowering the adoption barrier and embedding Torigen into the clinic workflow at the point of biopsy. Revenue is generated when clinics progress to VimClara immunotherapy production, with pricing not publicly disclosed. Customer acquisition runs primarily through veterinary clinic partnerships, supported by preferred distribution agreements with VerticalVet and Veterinary Management Groups that extend reach into affiliated clinic networks, and supplemented by direct inquiries from pet owners. The company also operates a dedicated clinic portal (torigen.vet) for order management and case tracking.

Torigen is a venture-backed private company that has raised approximately $16.1 million across multiple rounds, most notably a $13 million Series A1 in November 2022 co-led by Werth Family Investment Associates and Connecticut Innovations. The company is led by co-founder and CEO Ashley Kalinauskas, with Mark Suckow as co-founder and CTO and John Kallassy as CFO. Current operations are domestic, with primary geographic concentration in Connecticut and surrounding markets served through partner clinic networks.

Name

Torigen Pharmaceuticals

Legal name

Torigen, Inc.

Website

https://torigen.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

11–50 employees

Short description

Torigen Pharmaceuticals is a veterinary oncology company offering cancer diagnostics and personalized autologous immunotherapy vaccines for companion animals, serving veterinary clinics and pet owners primarily in the United States.

Ownership category

akta.pro rank

Product category

Veterinary Oncology Pharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Veterinary Services (54194), Medical Laboratories (621511)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)

akta.pro primary industry

Companion Animal Vaccines (Dogs & Cats) (HLAMAKAA)

akta.pro secondary industries

Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA) (HLAMAKAH), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary oncology products
• Autologous cancer vaccines
• Veterinary pathology services
• Pet cancer immunotherapy
• Animal health diagnostics

Headquarters

HQ city

Farmington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Immunotherapy Products and Services: Torigen generates revenue through the sale of personalized cancer immunotherapies and diagnostic services for veterinary patients. The VimClara kit enables veterinarians to produce personalized vaccines, while TSP provides pathology diagnostic services.
2. Specialty Pathology Diagnostics: Provides cancer diagnostic services to veterinary clinics through Torigen Specialty Pathology, offering expert pathological evaluations with rapid turnaround times.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Core offering

Torigen Pharmaceuticals develops and commercializes veterinary oncology products and services, anchored by VimClara, the first-ever autologous cancer vaccine kit that enables veterinarians to manufacture personalized cancer vaccines from a patient's own tumor tissue, and Torigen Specialty Pathology (TSP), which provides expert cancer diagnostic evaluations with a 3-6 day turnaround. Free Tumor Collection Kits (TCK) and TSP Kits funnel samples from veterinary clinics into the platform. The company serves veterinary clinics and pet owners seeking advanced cancer treatment options for companion animals.

Product overview

Torigen Pharmaceuticals offers a unified veterinary oncology platform combining comprehensive cancer diagnostics and individualized immunotherapy. The portfolio centers on Torigen Specialty Pathology (TSP) for expert pathological evaluations and VimClara, the first-ever autologous cancer vaccine kit that produces personalized cancer vaccines from a patient's own tumor tissue. Supporting products include the TSP Kit for formalin-fixed tissue histopathology and the Tumor Collection Kit (TCK) for fresh tissue submission with immunotherapy option preservation.

Differentiator

Problem solved

Functional benefit

Brands

• Torigen Specialty Pathology (TSP): Specialty pathology service combining speed, expertise, and accessibility for comprehensive cancer diagnostics in veterinary patients, offering 3-6 day turnaround time with expert pathologist analysis
• VimClara

Products and services

• VimClara The first-ever autologous cancer vaccine kit intended for the production of a personalized cancer vaccine from a patient's own tumor tissue, enabling veterinary clinics to offer advanced targeted immunotherapy to their cancer patients.
• Torigen Specialty Pathology (TSP) Comprehensive cancer diagnostics service that delivers fast, reliable pathological evaluations with a 3-6 day turnaround time from specialized pathologists, accessible to veterinary practices of all sizes. Sending tumor samples to TSP also opens the door to VimClara immunotherapy.
• TSP Kit Free sample-submission kit for veterinarians to send formalin-fixed tissue to Torigen Specialty Pathology for histopathology-only cases; these cases are not used for immunotherapy.
• Tumor Collection Kit (TCK) Free kit for submitting fresh (non-formalin) tumor tissue to Torigen for histopathology, with a representative sample preserved to enable VimClara immunotherapy if requested after diagnosis.

Quantifiable outcome

• 3-6 day turnaround time for cancer diagnostic reports

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered major.

• Veterinary Management GroupsmajorGTM or Marketing Partner · 1 April 2023Entered into a preferred partner agreement to provide cancer diagnostics and immunotherapy services to their network of affiliated veterinary practices. This partnership expands market access through established veterinary clinic networks.
• VerticalVetmajorChannel Partner/ Reseller/ Distributor · 1 December 2022Entered into a preferred partnership to distribute Torigen's specialty pathology and immunotherapy services through VerticalVet's veterinary clinic network. Enables broader market reach through existing distribution channels.

Scale indicators3 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• ELIAS Animal Health: ELIAS Animal Health develops immunotherapies for veterinary cancer patients, including autologous cancer vaccines. It is the closest direct competitor to Torigen's VimClara platform in the pet autologous immunotherapy category.

Broad incumbents

• Zoetis: Zoetis is the largest global animal health company with a broad portfolio of veterinary pharmaceuticals, vaccines, and diagnostics. It serves as the incumbent comparator in the broader veterinary oncology and animal biologics market where Torigen competes.
• IDEXX Laboratories: IDEXX is a leading veterinary diagnostics company offering in-clinic lab testing and reference lab services. It is comparable to Torigen's TSP diagnostic offering and represents the diagnostic incumbent in the veterinary oncology workflow.
• Antech Diagnostics: Antech Diagnostics, part of Mars Petcare, provides veterinary reference laboratory and imaging services across North America. It competes with Torigen Specialty Pathology in cancer diagnostic services for veterinary clinics.
• Virbac: Virbac is a global animal health company with a portfolio of veterinary pharmaceuticals, vaccines, and specialty products. Comparable to Torigen as a broader veterinary biologics and specialty therapeutics player.
• Heska Corporation: Heska (now part of Antech/Mars Petcare) sells in-clinic diagnostics, specialty veterinary products, and vaccines. Comparable to Torigen's integrated diagnostics-plus-treatment go-to-market in companion animal practices.

Emerging players

• PetCure Oncology: PetCure Oncology operates a network of veterinary radiation oncology clinics. It is an emerging player in the broader pet cancer treatment market and represents an alternative treatment modality that competes for clinic referrals.
• VetDC: VetDC develops and commercializes novel therapeutics for veterinary cancer patients. It is an emerging specialty oncology player targeting similar veterinary clinics and pet owners as Torigen.
• Ethos Veterinary Health: Ethos operates a network of specialty and emergency veterinary hospitals including oncology services. Comparable as a channel partner and customer base for Torigen's oncology offerings.
• BluePearl Specialty and Emergency Pet Hospital: BluePearl operates specialty veterinary hospitals including oncology services and is a potential clinic partner and customer for Torigen's VimClara and TSP offerings.

Market position

Strengths1 record

Competitive moat3 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/torigenpharmaceuticals
• LinkedInlinkedin.com/company/torigen-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds5 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Torigen Pharmaceuticals